Prospective clinical trial on dosage optimizing of tranexamic acid in non-emergency cardiac surgery procedures

Clinical Hemorheology and Microcirculation

Volumn 55, Issue 4, 2013, Pages 457-468

  Waldow, T ^a   Szlapka, M ^a   Haferkorn, M ^a   Burger L ^a   Plotze K ^a   Matschke, K ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFIBRINOLYTIC AGENT; TRANEXAMIC ACID;

AGED; CLINICAL TRIAL; COHORT ANALYSIS; DOSE RESPONSE; FEMALE; HEART SURGERY; HUMAN; MALE; PROCEDURES; PROSPECTIVE STUDY;

AGED; ANTIFIBRINOLYTIC AGENTS; CARDIAC SURGICAL PROCEDURES; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; PROSPECTIVE STUDIES; TRANEXAMIC ACID;

EID: 84893909232     PISSN: 13860291     EISSN: 18758622     Source Type: Journal    
DOI: 10.3233/CH-131782     Document Type: Article

References (33)

1. P. Alonso, P. Paniagua and P.J. Devereaux, Perioperative myocardial ischemia: Diagnosis, prognostic significance and therapeutic strategies in vascular surgery, Applied Cardiopulmonary Pathophysiology 17 (2013), 34-36
2. L. Andersson, O. Eriksson, P.O. Hedlund, H. Kjellman and B. Lindqvist, Special considerations with regard to the dosage of tranexamic acid in patients with chronic renal diseases, Urol Res 6 (1978), 83-88.
3. T. Bove, M.G. Calabro and G. Landoni, et al., The incidence and risk of acute renal failure after cardiac surgery, J Cardiothorac Vasc Anesth 18 (2004), 442-445.
4. J.R. Brown, N.J. Birkmeyer and G.T. O'Connor, Meta-analysis comparing the effectiveness and adverse outcomes of antifibrinolytic agents in cardiac surgery, Circulation 115 (2007), 2801-2813.
5. V. Casati, D. Guzzon, M. Oppizzi, F. Bellotti, A. Franco, C. Gerli, M. Cossolini, G. Torri, G. Calori, S. Benussi and O. Alfieri, Tranexamic acid compared with high-dose aprotinin in primary elective heart operations: Effects on perioperative bleeding and allogeneic transfusions, J Thorac Cardiovasc Surg 120 (2000), 520-527.
6. M.C. Christensen, S. Krapf, A. Kempel and C. von Heymann, Costs of excessive postoperative hemorrhage in cardiac surgery, J Thorac Cardiovasc Surg 138 (2009), 687-693.
7. N.P. Dowd, J.M. Karski, D.C. Cheng, J.A. Carroll, R.N.Y. Lin, M.S.R.L. James, and J. Butterworth, Pharmacokinetics of Tranexamic Acid during Cardiopulmonary Bypass, Anesthesiology 97 (2002), 390-399.
8. J. Dunning, M. Versteegh, A. Fabbri, A. Pavie, P. Kolh, U. Lockowandt and S.A.M. Nashef, on behalf of the EACTS Audit and Guidelines Committee, Guideline on antiplatelet and anticoagulation management in cardiac surgery, Eur J Cardiothorac Surg 34 (2008), 73-92
9. D.A. Fergusson, P.C. Hebert, C.D. Mazer, S. Fremes, C. MacAdams, J.M. Murkin, K. Teoh, P.C. Duke, R. Arellano, M.A. Blajchman, J.S. Bussieres, D. Cote, J. Karski, R. Martineau, J.A. Robblee, M. Rodger, G. Wells, J. Clinch and R. Pretorius, for the BART Investigators, A comparison of aprotinin and lysine analogues in high-risk cardiac surgery, N Engl J Med 358 (2008), 2319-2331.
10. B.K. Fiechtner, G.A. Nuttall, M.E. Johnson, Y. Dong, N. Sujirattanawimol, W.C. Oliver Jr, R.S. Sarpal, L.J. Oyen and M.H. Ereth, Plasma tranexamic acid concentrations during cardiopulmonary bypass, Anesth Analg 92 (2001), 1131-1136.
11. J.B. Gill, Y. Chin, A. Levin and D. Feng, The Use of Antifibrinolytic Agents in Spine Surgery: A Meta-Analysis, The Journal of Bone & Joint Surgery 90 (2008), 2399-2407.
12. J.F. Gummert, M.J. Barten, C. Hans, M.Kluge, N. Doll, T.Walther, B.Hentschel, D.V. Schmitt, F.W. Mohr andA.Diegeler, Mediastinitis, Cardiac, Surgery,-an Updated Risk Factor Analysis in 10, 373 Consecutive Adult Patients, Thorac Cardiov Surg 50 (2002), 87-91.
13. D.A. Henry, P.A. Carless, A.J. Moxey, D. O'Connell, B.J. Stokes, D.A. Fergusson and K. Ker, Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion (Review), The Cochrane Library (2011), Issue 3
14. B.J. Hunt and H. Segal, Hyperfibrinolysis, J Clin Pathol 49 (1996), 958.
15. F. Jung, S. Braune and A. Lendlein, Haemocompatibility testing of biomaterials using human platelets, Clin Hemorheol Microcirc 53 (2013), 97-115.
16. D. Kalavrouziotis, P. Voisine, S. Mohammadi, S. Dionne and F. Dagenais, High-Dose Tranexamic Acid Is an Independent Predictor of Early Seizure After Cardiopulmonary Bypass, Ann Thorac Surg 93 (2012), 148-155.
17. S. Karthik, A.D. Grayson, E.E. McCarron, D.M. Pullan and M.J. Desmond, Reexploration for Bleeding After Coronary Artery Bypass Surgery: Risk Factors, Outcomes, and the Effect of Time Delay, Ann Thorac Surg 78 (2004), 527-534.
18. A. Kumar, M. Suneja, E.O. Bayman, G.D. Weide and M. Tarasi, Association Between Postoperative Acute Kidney Injury and Duration of Cardiopulmonary Bypass: A Meta-Analysis, Journal of Cardiothoracic and Vascular Anesthesia 26(1) (2012), 64-69.
19. A.S. Levey, T. Greene, J.W. Kusek and G.J. Beck, MDRD Study Group, Simplified equation to predict glomerular filtration rate from serum creatinine, J Am Soc Nephrol 11 (2000), A0828.
20. D.T. Mangano, Y. Miao, A. Vuylsteke, I.C. Tudor, R. Juneja, D. Filipescu, A. Hoeft, M.L. Fontes, Z. Hillel, E. Ott, T. Titov, C. Dietzel and J. Levin, Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery, JAMA 297 (2007), 471-479.
21. D.T. Mangano, I.C. Tudor and C. Dietzel, for the Multicenter Study of Perioperative Ischemia Research Group, Ischemia Research and Education Foundation. The risk associated with aprotinin in cardiac surgery, N Engl J Med 354 (2006), 353-365.
22. M.J. Moulton, L.L. Creswell, M.E. Mackey, J.L. Cox and M. Rosenbloom, Reexploration for bleeding is a risk factor for adverse outcomes after cardiac operations, J Thorac Cardiovasc Surg 111 (1996), 1037-1046.
23. D.L. Ngaage and J.M. Bland, Lessons from aprotinin: Is the routine use and inconsistent dosing of tranexamic acid prudent? Meta-analysis of randomised and large matched observational studies, Eur J Cardiothor Surg 37 (2010), 1375-1383.
24. D. Paparella, S.J. Brister and M.R. Buchanan, Coagulation disorders of cardiopulmonary bypass: A review, Intensive Care Med 30 (2004), 1873-1881.
25. J. Papp, P. Kenyeres and K. Toth, Clinical importance of antiplatelet drugs in cardiovascular diseases, Clin Hemorheol Microcirc 53 (2013), 81-96.
26. EMA Press Release 02/17/2012; European Medicines Agency recommends lifting suspension of aprotinin, EMA/CHMP/119704/2012:1-3.
27. M. Ranucci, G. Bozzetti, A. Ditta, M. Cotza, G. Carboni and A. Ballotta, Surgical Reexploration After Cardiac Operations: Why a Worse Outcome? Ann Thorac Surg 86 (2008), 1557-1562.
28. W.H. Reinhart, Platelets in vascular disease, Clin Hemorheol Microcirc 53 (2013), 571-579.
29. S. Salis, V.V. Mazzanti, G. Merli, L. Salvi, C.C. Tedesco, F. Veglia and E. Sisillo, Cardiopulmonary Bypass, Duration, Is an Independent Predictor of Morbidity and Mortality After Cardiac Surgery, Journal of Cardiothoracic and Vascular Anesthesia 22 (2008), 814-822.
30. R.M. Sniecinski and J.H. Levy, MD, Bleeding and management of coagulopathy, J Thorac Cardiovasc Surg 142 (2011), 662-667.
31. A. Vuylsteke, C. Pagel, C. Gerrard, B. Reddy, S. Nashef, P. Aldam and M. Utley, The Papworth Bleeding Risk Score: A stratification scheme for identifying cardiac surgery patients at risk of excessive early postoperative bleeding, Eur J Cardiothorac Surg 39 (2011), 924-930.
32. T. Waldow, D. Krutzsch, M. Wils, K. Ploetze and K. Matschke, Low Dose Aprotinin and Low Dose Tranexamic Acid in Elective Cardiac Surgery with Cardiopulmonary Bypass, Clin Hemorheol Microcirc 42 (2009), 269-277.
33. T. Waldow, M. Szlapka, J. Hensel, K. Plötze, K. Matschke and L. Jatzwauk, Skin sealant Integu Seal(®) has no impact on prevention of postoperative mediastinitis after cardiac surgery, J Hosp Infect 81 (2012), 278-282.